Junshi Biosciences' Oncology Drug Toripalimab Obtains Marketing Approval in India and Hong Kong SAR

Junshi Biosciences' Oncology Drug Toripalimab Obtains Marketing Approval in India and Hong Kong SAR

By, Admin 17 October 2024

Overview

Toripalimab is the first and only treatment for nasopharyngeal carcinoma approved in India and China’s Hong Kong SAR.Shanghai Junshi Biosciences Co. and its wholly-owned subsidiary, TopAlliance Biosciences Inc., has announced that toripalimab (Indian trade name: ZYTORVI, Hong Kong trade name: LOQTORZI) has been approved for marketing in India and China’s Hong Kong Special Administrative Region (SAR), for treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC).

List of approved indication

The Approved Indications are: 

  1. toripalimab in combination with cisplatin and gemcitabine, for first line treatment of adults with metastatic or with recurrent, locally advanced NPC; 
  2. toripalimab as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy. 

Zytorvi shall be imported and commercialised in India by Dr. Reddy’s Laboratories Ltd.

About the Tumor: Nasopharyngeal Carcinoma 

  • NPC is a malignant tumour that occurs in the epithelium of the nasopharynx. 
  • According to GLOBOCAN 2022 statistics, the number of newly diagnosed NPC cases in 2022 exceeded 120,000 worldwide. 
  • Due to the location of the primary tumour, surgery is rarely an option. 
  • Toripalimab is the first and only treatment for NPC approved in India and China’s Hong Kong SAR.

Different Approvals for Toripalimab

  • In Asia, toripalimab obtained import license from the National Regulatory Authority (NRA) of India in September 2024, and marketing approval from Pharmacy and Poisons Board of China’s Hong Kong SAR in October 2024, for the treatment of recurrent or metastatic NPC. 
  • In Singapore, the new drug application (NDA) was accepted by the Singapore Health Sciences Authority (HSA) in January 2024. 
  • The HSA has also granted priority review designation for the NDA.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!